Zydus Lifesci.

Is Zydus Lifesci. overvalued or undervalued?

As of May 20, 2025, Zydus Lifesciences is considered undervalued and attractive with a PE ratio of 20.61, outperforming peers like Sun Pharma and Divi's Lab, and demonstrating strong long-term growth despite recent underperformance against the Sensex.

As of 20 May 2025, the valuation grade for Zydus Lifesciences has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 20.61, an EV to EBITDA ratio of 13.04, and a PEG ratio of 0.92, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Zydus Lifesciences stands out as attractive against Sun Pharma, which is considered expensive with a PE ratio of 35.25, and Divi's Lab, which is very expensive at a PE ratio of 79.33. Additionally, Zydus has a higher ROCE of 31.73% compared to Cipla's 22.99%, reinforcing its strong operational efficiency. While the stock has underperformed the Sensex over the past year, it has shown significant gains over a three and five-year period, indicating a robust long-term growth trajectory.

Who are the top shareholders of the Zydus Lifesci.?

The top shareholders of Zydus Lifesci include the Zydus Family Trust with 74.96%, mutual funds at 6.36%, foreign institutional investors at 7.32%, and the Life Insurance Corporation of India at 3.85%, while individual investors hold about 5.41%.

The top shareholders of Zydus Lifesci include the Zydus Family Trust, which holds the highest stake at 74.96%. Other significant shareholders are mutual funds, which collectively hold 6.36%, and foreign institutional investors (FIIs), with a combined holding of 7.32%. The highest public shareholder is the Life Insurance Corporation of India, owning 3.85%. Additionally, individual investors hold about 5.41% of the company.

Who are in the management team of Zydus Lifesci.?

As of March 2022, the management team of Zydus Lifesci includes Chairman Pankaj R Patel, Managing Director Sharvil P Patel, and several independent directors, along with executive and compliance roles, ensuring effective governance and strategic direction.

As of March 2022, the management team of Zydus Lifesci includes the following individuals:<BR><BR>1. **Pankaj R Patel** - Chairman (Non-Executive)<BR>2. **Sharvil P Patel** - Managing Director<BR>3. **Mukesh M Patel** - Director<BR>4. **Nitin Raojibhai Desai** - Independent Director<BR>5. **Dharmishta N Rawal** - Independent Director<BR>6. **Apurva S Diwanji** - Independent Director<BR>7. **Ganesh N Nayak** - Executive Director<BR>8. **Bhadresh K Shah** - Independent Director<BR>9. **Dhaval N Soni** - Company Secretary & Compliance Officer<BR>10. **Akhil A. Monappa** - Independent Director<BR>11. **Upasana Konidela** - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What is the bonus history of the Zydus Lifesci.?

Zydus Lifesciences Ltd has issued bonuses in the past, with the most recent being a 1:2 bonus on April 5, 2010, and a 1:1 bonus on August 30, 2006. These actions reflect the company's commitment to enhancing shareholder value.

Zydus Lifesciences Ltd has a history of issuing bonuses. The most recent bonus was a 1:2 bonus issue, which was announced with an ex-date of April 5, 2010, and the record date was April 6, 2010. Prior to that, the company issued a 1:1 bonus on August 30, 2006, with a record date of August 31, 2006. This indicates that Zydus Lifesciences has engaged in bonus issues to enhance shareholder value in the past.

Who are the peers of the Zydus Lifesci.?

Zydus Lifesci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Lupin, Aurobindo Pharma, Abbott India, Alkem Lab, and GlaxoSmithKline Pharma. Zydus Lifesci. has good management risk and growth, but its 1-year return is -9.94%, the lowest among its peers.

Peers: The peers of Zydus Lifesci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Lupin, Aurobindo Pharma, Abbott India, Alkem Lab, and Glaxosmi. Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, and the rest. Good management risk is found at Zydus Lifesci., Divi's Lab., Torrent Pharma, and Lupin. Average management risk is noted at Lupin. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Zydus Lifesci., and Lupin, while below average growth is seen at Divi's Lab., Torrent Pharma, Aurobindo Pharma, and Alkem Lab. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab, while good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Zydus Lifesci. has the lowest at -9.94%. Zydus Lifesci.'s return is significantly lower than the highest peer. Additionally, the peers with negative six-month returns include Zydus Lifesci., Lupin, Aurobindo Pharma, and Alkem Lab.

What does Zydus Lifesci. do?

Zydus Lifesciences Ltd is a major Indian pharmaceutical and biotechnology company, formerly known as Cadila Healthcare, with recent net sales of ₹65,279 Cr and a net profit of ₹11,709 Cr for Q1 2025. It has a market cap of ₹97,363 Cr and key metrics include a P/E ratio of 21.00 and a dividend yield of 0.31%.

Overview:<BR>Zydus Lifesciences Ltd is a leading innovation-driven pharmaceutical company in India, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap entity.<BR><BR>History:<BR>Zydus Lifesciences Ltd was formerly known as Cadila Healthcare Limited. The company is currently reporting its financial results for the quarter ending March 2025, with net sales and profit figures available for this period.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 65,279 Cr (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 11,709 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 97,363 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.31%<BR>Debt-Equity: -0.19<BR>Return on Equity: 19.58%<BR>Price to Book: 4.06<BR><BR>Contact Details:<BR>Address: Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W Ahmedabad Gujarat : 382481<BR>Tel: 91-079-26868100<BR>Email: upen.shah@zyduscadila.com<BR>Website: http://www.zyduscadila.com

How big is Zydus Lifesci.?

As of 24th July, Zydus Lifesciences Ltd has a market capitalization of 97,006.00 Cr, with recent Net Sales of 23,241.50 Cr and a Net Profit of 4,525.50 Cr.

As of 24th July, Zydus Lifesciences Ltd has a market capitalization of 97,006.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, Zydus Lifesciences reported Net Sales of 23,241.50 Cr and a Net Profit of 4,525.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 23,953.10 Cr and Total Assets totaling 34,857.90 Cr.

How has been the historical performance of Zydus Lifesci.?

Zydus Lifesci has shown consistent growth in net sales and profits, with net sales increasing from ₹14,253.10 Cr in March 2020 to ₹23,241.50 Cr in March 2025, and profit after tax rising from ₹1,175.60 Cr to ₹4,614.80 Cr during the same period, indicating strong financial performance and operational efficiency.

Answer:<BR>The historical performance of Zydus Lifesci shows a consistent growth trend in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Zydus Lifesci's net sales have risen from 14,253.10 Cr in March 2020 to 23,241.50 Cr in March 2025, reflecting a strong upward trajectory. The total operating income has followed a similar pattern, increasing from 14,253.10 Cr in March 2020 to 23,241.50 Cr in March 2025. The operating profit (PBDIT) has also improved significantly, growing from 2,897.30 Cr in March 2020 to 7,328.00 Cr in March 2025, indicating enhanced operational efficiency. Profit before tax has surged from 1,495.40 Cr in March 2020 to 6,026.70 Cr in March 2025, while profit after tax has increased from 1,175.60 Cr to 4,614.80 Cr during the same period. The earnings per share have more than tripled, rising from 11.49 in March 2020 to 44.99 in March 2025. On the balance sheet, total assets have grown from 22,833.70 Cr in March 2020 to 34,857.90 Cr in March 2025, while total liabilities have decreased from 7,901.10 Cr to 0.00 Cr, showcasing a strong financial position. Cash flow from operating activities has also improved, increasing from 2,931.00 Cr in March 2020 to 6,776.00 Cr in March 2025, contributing to a positive net cash inflow in the latest fiscal year. Overall, Zydus Lifesci has demonstrated robust growth across key financial metrics over the past several years.

Is Zydus Lifesci. technically bullish or bearish?

As of December 1, 2025, Zydus Lifesci. has shifted to a mildly bearish trend, indicated by bearish signals in the MACD and Bollinger Bands, despite some mildly bullish daily moving averages.

As of 1 December 2025, the technical trend for Zydus Lifesci. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by bearish signals in the MACD and Bollinger Bands on both weekly and monthly time frames. The KST also indicates a mildly bearish trend. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish indicators. The RSI shows no signal, and Dow Theory indicates no trend in both weekly and monthly assessments. Overall, the strength of the bearish stance is supported by the prevailing trends across multiple indicators.

When is the next results date for Zydus Lifesciences Ltd?

The next results date for Zydus Lifesciences Ltd is February 9, 2026.

The next results date for Zydus Lifesciences Ltd is scheduled for February 9, 2026.

Are Zydus Lifesciences Ltd latest results good or bad?

Zydus Lifesciences Ltd's latest Q4 FY25 results show strong revenue growth with net sales up 16.22% year-on-year and net profit rising 8.68%, but margin volatility and rising operational costs raise concerns. Overall, the results are positive in terms of growth, but caution is advised due to these underlying challenges.

Zydus Lifesciences Ltd's latest results for Q4 FY25 present a mixed picture. On the positive side, the company reported impressive revenue growth, with net sales reaching ₹7,587 crores, marking a robust 16.22% increase year-on-year and a 10.53% increase sequentially. Additionally, the net profit for the quarter was ₹1,272.50 crores, reflecting an 8.68% year-on-year growth and a significant 22.11% increase compared to the previous quarter.<BR><BR>However, there are concerns regarding margin volatility. The operating margin for Q4 FY25 was 34.36%, which is a notable improvement from the previous quarter but highlights fluctuations throughout the year. The profit after tax (PAT) margin of 18.04% showed a year-on-year decline from 19.85%, indicating rising operational costs or competitive pressures.<BR><BR>Overall, while Zydus Lifesciences demonstrated strong top-line growth and solid profitability in the latest quarter, the volatility in margins and rising costs are factors that investors should consider carefully. The company's strong balance sheet, with zero long-term debt and a solid return on equity of 20.19%, adds to its strengths. Thus, the results can be seen as good in terms of growth, but the underlying challenges warrant a cautious approach.

Should I buy, sell or hold Zydus Lifesciences Ltd?

Has Zydus Lifesciences Ltd declared dividend?

Yes, Zydus Lifesciences Ltd has declared a 100% dividend, amounting to ₹11 per share, with an ex-date of July 25, 2025. The company has demonstrated strong total returns across various periods, particularly over the long term.

Zydus Lifesciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 11<BR>- Ex-date: Jul-25-2025<BR><BR>Dividend Yield: 1.06%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 15.01%, the dividend return was 0.11%, leading to a total return of 15.12%.<BR><BR>Over the past 6 months, the price return was 12.08%, the dividend return was 0.11%, resulting in a total return of 12.19%.<BR><BR>For the 1-year period, the price return was 16.37%, the dividend return was 1.32%, culminating in a total return of 17.69%.<BR><BR>In the 2-year timeframe, the price return was -4.8%, the dividend return was 1.50%, which resulted in a total return of -3.3%.<BR><BR>Over the last 3 years, the price return was 109.63%, the dividend return was 4.07%, leading to a total return of 113.7%.<BR><BR>In the 4-year period, the price return was 190.13%, the dividend return was 6.68%, resulting in a total return of 196.81%.<BR><BR>For the 5-year duration, the price return was 69.13%, the dividend return was 4.29%, culminating in a total return of 73.42%.<BR><BR>Overall, Zydus Lifesciences Ltd has declared a significant dividend and has shown strong total returns across multiple periods, particularly impressive over the longer term, indicating a positive performance trend.

Why is Zydus Lifesciences Ltd falling/rising?

As of 21-May, Zydus Lifesciences Ltd's stock price is at 1,036.20, down 0.46% after two days of gains. Despite this short-term decline, the stock has shown strong long-term performance, but concerns about recent financial results and sector underperformance may impact investor sentiment.

As of 21-May, Zydus Lifesciences Ltd's stock price is currently at 1,036.20, reflecting a decrease of 4.75 points or 0.46%. This decline comes after two consecutive days of gains, indicating a trend reversal. Despite this short-term drop, the stock has shown strong performance over longer periods, with a 1-week increase of 4.53% and a 1-month increase of 11.56%. <BR><BR>The stock is trading above its moving averages across various time frames, suggesting a generally positive trend in the longer term. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 190.83% compared to the 5-day average. This indicates a healthy level of trading activity, which can be a positive sign for future price movements.<BR><BR>However, the stock has underperformed its sector by 0.61% today, which may contribute to the current price decline. Furthermore, recent financial results showed flat performance in March, with a return on capital employed (ROCE) at its lowest for the half-year at 19.13%, and a higher debt-equity ratio of 0.46 times, which could raise concerns among investors.<BR><BR>In summary, while Zydus Lifesciences Ltd has demonstrated strong long-term growth and profitability, the recent price drop can be attributed to a combination of short-term trend reversal, sector underperformance, and concerns regarding recent financial results.

Which are the latest news on Zydus Lifesci.?